Leerink Partnrs Forecasts Lower Earnings for Inari Medical

Inari Medical, Inc. (NASDAQ:NARI) – Investment analysts at Leerink Partnrs decreased their FY2027 EPS estimates for Inari Medical in a report issued on Monday, November 25th. Leerink Partnrs analyst M. Kratky now expects that the company will earn $0.54 per share for the year, down from their prior forecast of $0.56. Leerink Partnrs has a “Hold” rating on the stock. The consensus estimate for Inari Medical’s current full-year earnings is ($0.77) per share. Leerink Partnrs also issued estimates for Inari Medical’s FY2028 earnings at $0.97 EPS.

Several other research analysts also recently commented on the stock. Piper Sandler boosted their price objective on shares of Inari Medical from $50.00 to $52.00 and gave the company a “neutral” rating in a research report on Tuesday, October 29th. Stifel Nicolaus assumed coverage on Inari Medical in a report on Tuesday, September 17th. They set a “hold” rating and a $50.00 price target for the company. Truist Financial upped their price objective on Inari Medical from $46.00 to $50.00 and gave the stock a “hold” rating in a research report on Tuesday, October 29th. Needham & Company LLC reissued a “hold” rating on shares of Inari Medical in a research note on Tuesday, October 29th. Finally, Robert W. Baird raised their price target on shares of Inari Medical from $66.00 to $67.00 and gave the company an “outperform” rating in a research note on Tuesday, October 29th. Six analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, Inari Medical presently has an average rating of “Hold” and a consensus target price of $58.89.

Inari Medical Trading Up 0.4 %

Shares of Inari Medical stock opened at $51.03 on Tuesday. The company has a market cap of $2.99 billion, a PE ratio of -37.65 and a beta of 0.96. The company has a 50 day moving average of $45.86 and a 200-day moving average of $47.43. Inari Medical has a 1-year low of $36.73 and a 1-year high of $67.13.

Hedge Funds Weigh In On Inari Medical

A number of hedge funds have recently made changes to their positions in the stock. GAMMA Investing LLC increased its position in Inari Medical by 164.7% during the 2nd quarter. GAMMA Investing LLC now owns 704 shares of the company’s stock valued at $34,000 after purchasing an additional 438 shares during the period. Nisa Investment Advisors LLC increased its position in shares of Inari Medical by 83.5% during the second quarter. Nisa Investment Advisors LLC now owns 956 shares of the company’s stock worth $46,000 after buying an additional 435 shares during the period. KBC Group NV increased its position in shares of Inari Medical by 39.0% during the third quarter. KBC Group NV now owns 1,774 shares of the company’s stock worth $73,000 after buying an additional 498 shares during the period. Benjamin F. Edwards & Company Inc. raised its stake in Inari Medical by 39.4% during the second quarter. Benjamin F. Edwards & Company Inc. now owns 1,847 shares of the company’s stock worth $89,000 after buying an additional 522 shares during the last quarter. Finally, Covestor Ltd lifted its holdings in Inari Medical by 63.5% in the third quarter. Covestor Ltd now owns 2,384 shares of the company’s stock valued at $99,000 after buying an additional 926 shares during the period. 90.98% of the stock is currently owned by institutional investors.

Insider Activity

In related news, Director William Hoffman sold 40,000 shares of the business’s stock in a transaction on Monday, September 16th. The shares were sold at an average price of $45.83, for a total value of $1,833,200.00. Following the sale, the director now owns 643,296 shares of the company’s stock, valued at $29,482,255.68. The trade was a 5.85 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Andrew Hykes sold 3,000 shares of the stock in a transaction on Tuesday, October 29th. The shares were sold at an average price of $50.00, for a total value of $150,000.00. Following the completion of the sale, the chief executive officer now owns 445,310 shares of the company’s stock, valued at $22,265,500. The trade was a 0.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 186,000 shares of company stock valued at $8,990,990 over the last quarter. 10.60% of the stock is owned by company insiders.

Inari Medical Company Profile

Inari Medical, Inc builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation.